title: PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.
abstract: There has been increasing interest in the use of isoform-selective inhibitors of phosphatidylinositide-3-kinase (PI3K) in cancer therapy. Using conditional deletion of the p110 catalytic isoforms of PI3K to predict sensitivity of cancer types to such inhibitors, we and others have demonstrated that tumors deficient of the phosphatase and tensin homolog (PTEN) are often dependent on the p110β isoform of PI3K. Because human cancers usually arise due to multiple genetic events, determining whether other genetic alterations might alter the p110 isoform requirements of PTEN-null tumors becomes a critical question. To investigate further the roles of p110 isoforms in PTEN-deficient tumors, we used a mouse model of ovarian endometrioid adenocarcinoma driven by concomitant activation of the rat sarcoma protein Kras, which is known to activate p110α, and loss of PTEN. In this model, ablation of p110β had no effect on tumor growth, whereas p110α ablation blocked tumor formation. Because ablation of PTEN alone is often p110β dependent, we wondered if the same held true in the ovary. Because PTEN loss alone in the ovary did not result in tumor formation, we tested PI3K isoform dependence in ovarian surface epithelium (OSE) cells deficient in both PTEN and p53. These cells were indeed p110β dependent, whereas OSEs expressing activated Kras with or without PTEN loss were p110α dependent. Furthermore, isoform-selective inhibitors showed a similar pattern of the isoform dependence in established Kras(G12D)/PTEN-deficient tumors. Taken together, our data suggest that, whereas in some tissues PTEN-null tumors appear to inherently depend on p110β, the p110 isoform reliance of PTEN-deficient tumors may be altered by concurrent mutations that activate p110α.
authors.affiliation: Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115.
authors.forename: Fabienne
authors.initials: F
authors.lastname: Schmit
authors.forename: Tamara
authors.initials: T
authors.lastname: Utermark
authors.forename: Sen
authors.initials: S
authors.lastname: Zhang
authors.forename: Qi
authors.initials: Q
authors.lastname: Wang
authors.forename: Thanh
authors.initials: T
authors.lastname: Von
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Roberts
authors.forename: Jean J
authors.initials: JJ
authors.lastname: Zhao
mesh_terms: D000818:Animals; D063646:Carcinogenesis / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects; D004195:Disease Models, Animal; D004847:Epithelial Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007527:Isoenzymes / Q000378:metabolism; D051379:Mice; D010051:Ovarian Neoplasms / Q000201:enzymology* / Q000235:genetics* / Q000473:pathology; D051059:PTEN Phosphohydrolase / Q000172:deficiency* / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D016283:Proto-Oncogene Proteins p21(ras) / Q000378:metabolism; D051381:Rats
chemical_list: D007527:Isoenzymes; D051059:PTEN Phosphohydrolase; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D016283:Proto-Oncogene Proteins p21(ras); C487757:Pten protein, mouse; C495971:Hras protein, mouse
keywords: PI3K inhibitors; genetically engineered mouse model; ovarian cancer
references.citation: J Clin Oncol. 2006 Oct 10;24(29):4783-91
references.pmid: 17028294
references.citation: Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8292-7
references.pmid: 18544649
references.citation: Nat Rev Clin Oncol. 2013 Mar;10(3):143-53
references.pmid: 23400000
references.citation: Nature. 2008 May 29;453(7195):662-6
references.pmid: 18449193
references.citation: Cancer Cell. 2004 Apr;5(4):375-87
references.pmid: 15093544
references.citation: Oncogene. 2008 Sep 18;27(41):5497-510
references.pmid: 18794884
references.citation: Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16296-300
references.pmid: 17060635
references.citation: J Clin Invest. 2012 Feb;122(2):553-7
references.pmid: 22214849
references.citation: J Clin Endocrinol Metab. 2008 Aug;93(8):3106-16
references.pmid: 18492751
references.citation: Nat Genet. 2007 Mar;39(3):347-51
references.pmid: 17293865
references.citation: Cell. 2013 May 23;153(5):1050-63
references.pmid: 23706742
references.citation: Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18443-8
references.pmid: 16339315
references.citation: Cancer Cell. 2007 Apr;11(4):321-33
references.pmid: 17418409
references.citation: Biochem J. 2008 Oct 1;415(1):97-110
references.pmid: 18498248
references.citation: Nat Rev Mol Cell Biol. 2012 Apr 04;13(5):283-96
references.pmid: 22473468
references.citation: Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):19897-902
references.pmid: 21030680
references.citation: Science. 2007 Nov 16;318(5853):1108-13
references.pmid: 17932254
references.citation: Nat Rev Drug Discov. 2009 Aug;8(8):627-44
references.pmid: 19644473
references.citation: J Clin Invest. 2011 Nov;121(11):4311-21
references.pmid: 21985784
references.citation: Genes Dev. 2012 Jul 15;26(14):1573-86
references.pmid: 22802530
references.citation: Curr Top Microbiol Immunol. 2010;346:143-69
references.pmid: 20563706
references.citation: Cancer Res. 2008 Oct 1;68(19):8127-36
references.pmid: 18829572
references.citation: Curr Opin Cell Biol. 2009 Apr;21(2):199-208
references.pmid: 19200708
references.citation: Mol Biol Cell. 2010 Mar 1;21(5):704-11
references.pmid: 20053680
references.citation: Science. 1997 Jun 20;276(5320):1848-50
references.pmid: 9188528
references.citation: Expert Opin Investig Drugs. 2012 Jan;21(1):15-22
references.pmid: 22112004
references.citation: Cell Cycle. 2007 Dec 1;6(23):2902-5
references.pmid: 17993782
references.citation: Nat Rev Mol Cell Biol. 2010 May;11(5):329-41
references.pmid: 20379207
references.citation: Cell. 2006 May 19;125(4):733-47
references.pmid: 16647110
references.citation: Cell. 2007 Jun 1;129(5):957-68
references.pmid: 17540175
references.citation: Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13057-62
references.pmid: 18755892
references.citation: Cancer Cell. 2003 May;3(5):483-95
references.pmid: 12781366
references.citation: Science. 2004 Apr 23;304(5670):554
references.pmid: 15016963
references.citation: Clin Cancer Res. 2008 Feb 15;14(4):1172-81
references.pmid: 18281552
references.citation: Nature. 2008 Aug 7;454(7205):776-9
references.pmid: 18594509
references.citation: Nat Rev Cancer. 2005 Dec;5(12):921-9
references.pmid: 16341083
references.citation: Cancer Discov. 2012 May;2(5):425-33
references.pmid: 22588880
references.citation: Cancer Discov. 2013 May;3(5):548-63
references.pmid: 23454899
references.citation: Biochem J. 2012 Feb 15;442(1):151-9
references.pmid: 22150431
references.citation: Int J Mol Sci. 2013 May 02;14(5):9536-55
references.pmid: 23644885
references.citation: Nat Med. 2005 Jan;11(1):63-70
references.pmid: 15619626
references.citation: Bioorg Med Chem Lett. 2013 Jul 1;23(13):3741-8
references.pmid: 23726034
references.citation: Blood. 2010 Mar 11;115(10):2008-13
references.pmid: 20065293
references.citation: Mol Cell. 2011 Mar 4;41(5):499-501
references.pmid: 21362546
references.citation: Genes Dev. 2001 Dec 15;15(24):3243-8
references.pmid: 11751630
references.citation: Genes Dev. 2013 Jul 15;27(14):1568-80
references.pmid: 23873941
references.citation: Nat Rev Genet. 2006 Aug;7(8):606-19
references.pmid: 16847462
references.citation: Cancer Discov. 2013 Jan;3(1):44-51
references.pmid: 23258246